38 results on '"Peggs, Karl"'
Search Results
2. Lymphocyte morphology in a patient receiving CD19 chimeric antigen receptor T‐cell therapy for mantle cell lymphoma
3. Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report
4. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
5. Comparative analysis of melphalan versus busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia
6. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
7. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
8. The function and dysfunction of memory CD8+T cells in tumor immunity
9. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
10. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
11. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols
12. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
13. Recent advances in antibody-based therapies for Hodgkin Lymphoma
14. Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma
15. Antifungal stewardship: towards defining safe stopping criteria for therapeutic oral azoles
16. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure
17. Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
18. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma
19. Allogeneic transplantation in the UK: an aggregation of marginal gains?
20. Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning
21. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
22. Mini‐BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage‐refractory DLBCL
23. Management of multidrug-resistant viruses in the immunocompromised host
24. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure
25. Autologous stem cell transplantation remains beneficial for patients relapsing after R‐CHOP chemotherapy and who respond to salvage chemotherapy
26. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
27. Allogeneic transplantation for Hodgkin lymphoma
28. Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
29. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
30. The role of allogeneic transplantation in non-Hodgkin's lymphoma
31. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
32. Immune reconstitution following haematopoietic stem cell transplantation
33. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma
34. T‐ and B‐cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T‐cell‐depleted, reduced‐intensity allogeneic stem cell transplantation with an alemtuzumab‐containing conditioning regimen followed by escalated donor lymphocyte infusions
35. Assessing diversity: immune reconstitution and T‐cell receptor BV spectratype analysis following stem cell transplantation
36. Cytomegalovirus infection and disease after autologous peripheral blood stem cell transplantation
37. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
38. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.